RxDoctor Payments Data

Sayed Ali, MD

Nephrology · Manhasset, NYNPI 1194721191

Payments from drug & device makers

$119,328in general payments, 2019–2025

Across 503 payments — averaging $237.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$110K
  • Amgen$2K
  • Mallinckrodt Hospital Products Inc.$882
  • Otsuka America Pharmaceutical, Inc.$787
  • Vifor Pharma, Inc.$694
  • OPKO Pharmaceuticals, LLC$588
  • plus $4K from 31 others

What the payments were for

  • Consulting fees$1,2243%
  • Speaking & faculty fees$27,57867%
  • Travel & lodging$1,2703%
  • Food & beverage$10,94926%
  • Education$4321%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$119,328 in reported general payments places this provider in the 90th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$358,775
Medicare patients
499
Services billed
9,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol80$111,473
LokelmaSodium Zirconium Cyclosilicate70$95,125
OzempicSemaglutide35$50,769
Cinacalcet Hcl35$47,191
JardianceEmpagliflozin23$35,891
EliquisApixaban26$35,664
TrulicityDulaglutide11$11,059
JanuviaSitagliptin Phosphate14$11,047
Lanthanum Carbonate11$11,040
Sevelamer Carbonate28$4,382
Tacrolimus14$3,312
Olmesartan Medoxomil65$1,607
Nifedipine ErNifedipine28$1,198
Midodrine Hcl14$1,170
Metolazone39$1,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$110,284$206,599150 claims
Novo NordiskOzempic$324$50,76935 claims
Boehringer IngelheimJardiance$108$35,89123 claims
PfizerEliquis$32$35,66426 claims
Lilly USA, LLCTrulicity$224$11,05911 claims
ANI Pharmaceuticals, Inc.Valsartan$323$80229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 nephrology providers in New York.

Other nephrology in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →